Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis
NCT07756840Phase 2Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 2 trial of tazemetostat, bevacizumab in recurrent respiratory papillomatosis (RRP), sponsored by National Cancer Institute. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
tazemetostatbevacizumab
03
Conditions
recurrent respiratory papillomatosis (RRP)
Beyond the preview
Go deeper on NCT07756840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07756840.